SOX方案联合沙利度胺治疗Her-2阴性晚期胃癌的临床研究  

Clinical Study of SOX Regimen Combined with Thalidomide in Treatment of Her-2 Negative Advanced Gastric Cancer

作　　者：王玲 邱志敏[2] 戴月 WANG Ling;QIU Zhimin;DAI Yue(Nanchang Medical College,Jiangxi Health Vocational College,Nanchang Jiangxi 330052,China;Jiangxi Cancer Hospital,Nanchang Jiangxi 330029,China)

机构地区：[1]南昌医学院,江西卫生职业学院,江西南昌330052 [2]江西省肿瘤医院,江西南昌330029

出　　处：《药品评价》2024年第10期1221-1224,共4页Drug Evaluation

基　　金：江西省教育厅科学技术研究项目(GJJ2208205)。

摘　　要：目的探讨SOX方案联合沙利度胺治疗Her-2阴性晚期胃癌的效果。方法选取2022年1月至2023年12月江西省肿瘤医院收治的80例Her-2阴性晚期胃癌患者,随机分为对照组(40例)、观察组(40例)。对照组采用常规SOX方案化疗,观察组采用SOX方案联合沙利度胺治疗。治疗2周期后观察两组近期临床疗效、血清血管内皮生长因子(VEGF)、肿瘤坏死因子-α(TNF-α)水平、免疫功能指标以及药物不良反应。结果观察组疾病控制率高于对照组,差异有统计学意义(P<0.05);观察组客观缓解率高于对照组,差异无统计学意义(P>0.05)。治疗后,两组VEGF、TNF-α水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组,差异有统计学意义(P<0.05);观察组CD8^(+)与对照组差异无统计学意义(P>0.05)。观察组不良反应中白细胞减少和恶心呕吐发生率低于对照组,便秘发生率高于对照组,差异有统计学意义(P<0.05)。结论SOX方案联合沙利度胺治疗Her-2阴性晚期胃癌,可以有效改善其近期疗效,增强患者免疫力,减轻患者不良反应,同时抑制血清中VEGF、TNF-α表达,达到增强抗肿瘤作用,值得在临床中推广应用。Objective To explore the effect of SOX regimen combined with thalidomide in the treatment of Her-2 negative advanced gastric cancer.Methods 80 patients with Her-2 negative advanced gastric cancer who were treated at Jiangxi Cancer Hospital from January 2022 to December 2023 were randomly divided into control group(40 cases)and observation group(40 cases).The control group received conventional SOX regimen,and the observation group was treated with SOX regimen combined with thalidomide.After 2 cycles of treatment,the recent clinical efficacy,serum VEGF,TNF-αlevels,immune function indicators and adverse drug reactions in both groups were observed.Results The disease control rate of observation group was higher than that of control group,the difference was statistically significant(P<0.05);the objective remission rate of observation group was higher than that of control group,and the difference was not statistically significant(P>0.05).After treatment,VEGF and TNF-αlevels in both groups were lower than before treatment,and observation group was lower than control group(P<0.05);CD3^(+),CD4^(+),CD4^(+)/CD8^(+)were higher in observation group than in control group(P<0.05);there was no statistically significant difference in CD8^(+)between the two groups(P>0.05).The incidence of leukopenia and nausea/vomiting in observation group were lower than those in the control group,and the incidence of constipation was higher than that in the control group,the differences were statistically significant(P<0.05).Conclusion SOX regimen combined with thalidomide in the treatment of Her-2 negative advanced gastric cancer can effectively improve its short-term efficacy,enhance the immunity of patients,reduce adverse reactions of patients,and inhibit the expression of VEGF and TNF-αin serum to enhance the anti-tumor effect,which is worthy of promotion and application in clinical practice.

关 键 词：SOX方案 沙利度胺 Her-2阴性 胃癌 

分 类 号：R735.2[医药卫生—肿瘤]